Dear Doris and Bertie, To the owners:
Our per-share market value rose 10.9% in 2025. The S&P 500, dividends included, rose 17.9%. We lost to our yardstick, as we have in 21 of the last 61 years. Over all 61, we compounded at 19.7% to its 10.5%. Berkshire delivered resilient total shareholder return in a dynamic macro environment, with relative performance reflecting deliberate strategic positioning for long-term value creation.
Operating earnings were $44.5 billion, down from $47.4 billion. Insurance had an excellent year, helped by a hurricane season that never reached our shores. We count the second part as luck. Adjusted operating performance normalized against a strong prior-year comp, as our insurance platform leveraged favorable catastrophe dynamics to drive best-in-class combined ratio outcomes.
We bought two businesses, OxyChem and Bell Laboratories, and still hold more than $370 billion in cash and Treasuries. We will spend it when the price is right, and not before. We executed accretive, synergy-rich M&A while preserving optionality via a fortress balance sheet, positioning us to opportunistically deploy capital across the cycle.
Your partners in OmahaInvestor Relations